Autolus Therapeutics (AUTL) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a sell rating to a hold rating in a research note published on Thursday, Zacks.com reports.

According to Zacks, “Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company’s pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. “

Several other analysts have also recently commented on the company. William Blair restated a buy rating on shares of Autolus Therapeutics in a report on Wednesday, April 3rd. HC Wainwright set a $45.00 price target on Autolus Therapeutics and gave the company a buy rating in a report on Wednesday, February 20th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $42.67.



Autolus Therapeutics stock opened at $21.08 on Thursday. The stock has a market cap of $846.28 million and a P/E ratio of -14.85. Autolus Therapeutics has a 52 week low of $19.17 and a 52 week high of $53.24. The company has a debt-to-equity ratio of 0.12, a current ratio of 10.66 and a quick ratio of 10.66.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.11). The company had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, sell-side analysts forecast that Autolus Therapeutics will post -3.07 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP grew its holdings in Autolus Therapeutics by 93.4% in the 1st quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock valued at $7,330,000 after buying an additional 112,489 shares during the period. CWM LLC purchased a new stake in Autolus Therapeutics in the 1st quarter valued at about $1,105,000. Geode Capital Management LLC purchased a new stake in Autolus Therapeutics in the 4th quarter valued at about $322,000. Barclays PLC purchased a new stake in Autolus Therapeutics in the 4th quarter valued at about $113,000. Finally, BlackRock Inc. grew its holdings in shares of Autolus Therapeutics by 4,011.3% during the 4th quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock worth $6,666,000 after purchasing an additional 198,036 shares during the period. Institutional investors own 41.81% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Further Reading: How are the companies in the S&P 500 selected?

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.